Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions

The past several years have seen unprecedented advances in the application of various therapeutic strategies for the treatment of patients with renal cancer. The availability of active immunotherapy, antiangiogenic therapy, and targeted therapy for this disease has brought front and center issues related to choosing the appropriate treatment for particular patient populations. It is increasingly evident that the most promising treatment selection strategies will incorporate identifying specific features of the tumor itself. To facilitate this move toward personalized medicine, it is critically important to establish some standard principles for renal cancer tissue collection, preparation, and analysis for translational research studies. In this article, we identify and discuss some critical issues related to tissue-based kidney cancer research. We focus on five major areas as follows: (a) surgical and image-guided techniques for tissue collection; (b) quality control of specimen collection, processing, storage, and review; (c) issues related to analysis of paraffin embedded tissues; (d) genomic studies; and (e) assessment of reproducibility of assays across institutions. In addition, some practical implementation strategies are proposed. Although many of the topics discussed are specific for renal cancer, several are also relevant to tissue based biomarker investigations in a broad array of malignancies.

[1]  S. Signoretti,et al.  Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. , 2007, Clinical genitourinary cancer.

[2]  Michael A S Jewett,et al.  Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. , 2007, The Journal of urology.

[3]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[4]  S. Signoretti,et al.  The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer , 2007, Clinical Cancer Research.

[5]  T. Libermann,et al.  Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead , 2007, Clinical Cancer Research.

[6]  Mark A Rosen,et al.  Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference , 2007, Clinical Cancer Research.

[7]  James Brugarolas,et al.  Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.

[8]  R. Motzer,et al.  Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[9]  R. Motzer,et al.  Novel targets and therapies for metastatic renal cell carcinoma. , 2006, Oncology.

[10]  V. Kaklamani,et al.  A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX , 2006, Expert review of molecular diagnostics.

[11]  Victor E Reuter,et al.  The pathology of renal epithelial neoplasms. , 2006, Seminars in oncology.

[12]  K. Chew,et al.  Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status , 2006, BJU international.

[13]  T. Hampton Trials probe new agents for kidney cancer. , 2006, JAMA.

[14]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[15]  A. Hanlon,et al.  The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. , 2006, The Journal of urology.

[16]  F. Pontén,et al.  Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens , 2006, Laboratory Investigation.

[17]  I. Mellinghoff,et al.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.

[18]  Marie Joseph,et al.  Gene Signatures of Progression and Metastasis in Renal Cell Cancer , 2005, Clinical Cancer Research.

[19]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[20]  J. Giltnane,et al.  Technology Insight: identification of biomarkers with tissue microarray technology , 2004, Nature Clinical Practice Oncology.

[21]  D. Rimm,et al.  Long-term preservation of antigenicity on tissue microarrays , 2004, Laboratory Investigation.

[22]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[23]  F. Rybicki,et al.  Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. , 2003, AJR. American journal of roentgenology.

[24]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[25]  D. Rossi,et al.  Fine-needle percutaneous biopsy of renal masses with helical CT guidance. , 2000, Radiology.

[26]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.

[27]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.